cc-90009
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02848001)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- CRL4(CRBN) E3 ubiquitin ligaseMODULATOR
CRL4(CRBN) E3 ubiquitin ligase modulator
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- cc-90009
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04336982 | Phase 1/Phase 2 (Phase 2) | May 26, 2020 | AbbVie, Celgene |
| NCT04297124 | Phase 1 | Mar 18, 2020 | Bristol-Myers Squibb, Celgene |
| NCT02848001 | Phase 1 | Nov 1, 2016 | Celgene |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celgene | For profit | 3 | 3 | 2 | 2016 |
| AbbVie | For profit | 1 | 0 | 1 | 2020 |
| Bristol-Myers Squibb | For profit | 1 | 0 | 1 | 2020 |
3 organizations
Page 1 / 1